Equities

Cannabis Poland SA

Cannabis Poland SA

Actions
  • Price (PLN)0.597
  • Today's Change0.024 / 4.19%
  • Shares traded424.69k
  • 1 Year change+67.23%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cannabis Poland SA, formerly Telehorse SA, is a Poland-based company engaged in the Pharmaceutical and Medicine Manufacturing activity. The Company focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The Company also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The Company is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.

  • Revenue in PLN (TTM)199.93k
  • Net income in PLN-675.76k
  • Incorporated2012
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Private Rented Sector SA200.00k27.20k8.46m--310.83--90.1942.290.02060.02060.1514-0.0351.79--2.20--24.281,266.23----23.89-1,935.5513.602,755.44-------------66.26------
Inno-Gene SA1.13m-1.46m10.15m27.00--1.54--9.00-0.2559-0.25590.19791.160.10864.670.673---14.047.92-19.0710.7339.1873.63-129.3411.592.58--0.0362---93.08-16.73-542.12------
Braster SA1.31m-3.83m16.24m16.00------12.42-0.2825-0.28250.0561-0.17340.06010.0769163.38---17.61-29.23-220.50-50.2771.1668.77-293.04-1,435.540.3061-2.591.62--413.7641.3542.87------
Sygnis SA15.75m-8.22m17.52m--------1.11-0.3614-0.36140.6925-------------6.10---9.5750.8256.46-53.74-22.44---10.62-----33.3844.26-266.18------
Nanogroup SA2.02k-7.89m20.50m----4.58--10,148.22-0.3926-0.39260.00010.22280.000217.600.0349---56.82-23.18-67.19-26.06-47,764.85-278.03-391,395.10-1,567.570.5186-2,409.120.00---98.55-55.07-840.84---8.99--
Stem Cells Spin SA-100.00bn-100.00bn21.49m----2.89----------0.1797-----------1.14---1.93--94.37---45.340.0363--0.0153--68.84-4.37-678.77---52.67--
Genxone SA2.39m-3.72m23.01m----1.54--9.61-1.13-1.130.72654.540.135813.395.04---21.0914.58-22.0416.46-23.1848.42-155.3120.4116.91--0.0039---77.38111.39-874.87---28.78--
Pure Biologics SA109.00k-31.72m23.30m53.00--1.79--213.78-11.15-11.150.03774.050.0023--0.10261,135.42-66.46-48.68-81.74-83.38-3,960.5538.81-29,097.25-195.73---11.410.7606--160.63-7.58-117.62------
Cannabis Poland SA199.93k-675.76k29.37m----53.93--146.92-0.0255-0.02550.00760.01110.30180.82645.07---102.76-116.92-175.94-136.3026.1612.29-340.53-959.391.35-45.880.2547---47.5550.2314.30------
GENOMED SA22.48m996.34k38.85m--38.993.8424.051.730.75410.754117.017.662.006.2913.81--8.877.9010.249.3342.8538.564.433.934.103,257.61----9.853.87193.38-7.69-32.19--
Data as of May 10 2024. Currency figures normalised to Cannabis Poland SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.